These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 24619317)

  • 21. [Effects of statins on coronary artery disease. Review of the recent publications].
    Bednarz B
    Przegl Lek; 2003; 60(1):27-9. PubMed ID: 12884643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinical focus on statins.
    Auer J; Eber B
    Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. By the way, doctor. I have high cholesterol, and have been taking Mevacor (lovastatin) for two years. Recently, I was switched to Pravachol (pravastatin) because my insurance company would no longer pay for Mevacor. Is it as good?
    Nicholson CR
    Harv Womens Health Watch; 1999 Jun; 6(10):8. PubMed ID: 10233830
    [No Abstract]   [Full Text] [Related]  

  • 26. Potential neurological value of statins increases.
    Bonetta L
    Nat Med; 2002 Jun; 8(6):541. PubMed ID: 12042786
    [No Abstract]   [Full Text] [Related]  

  • 27. Fluvastatin: what is the evidence?
    Bagg W; Braatvedt G
    N Z Med J; 1997 Aug; 110(1050):321-2. PubMed ID: 9315035
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevention of coronary heart disease: incremental cost effectiveness raises issues.
    D'Avanzo WC
    BMJ; 2004 Feb; 328(7436):405; author reply 405. PubMed ID: 14962886
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cost-effectiveness of coronary heart disease prevention].
    Wendland G; Klever-Deichert G; Lauterbach K
    Z Kardiol; 2002; 91 Suppl 2():49-60. PubMed ID: 12436765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cost-effectiveness of statins. Review].
    Moriguchi H; Goto Y
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():513-7. PubMed ID: 11347123
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevention of coronary heart disease: data in table 2 could be shown more explicitly for better understanding.
    Messori A; Santarlasci B
    BMJ; 2004 Feb; 328(7436):405; author reply 405. PubMed ID: 14962887
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway.
    Cook JR; Yin D; Alemao E; Davies G; Krobot KJ; Veltri E; Lipka L; Badia X
    Pharmacoeconomics; 2004; 22 Suppl 3():49-61. PubMed ID: 15669153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
    Barry M; Heerey A
    Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692
    [No Abstract]   [Full Text] [Related]  

  • 35. Statin therapy for elevated hsCRP: more evidence is needed.
    Molokwu OC
    Am J Manag Care; 2010 Aug; 16(8):565-6. PubMed ID: 20712389
    [No Abstract]   [Full Text] [Related]  

  • 36. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins for cardiovascular prevention according to different strategies: a cost analysis.
    Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
    Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atorvastatin: a new agent for hyperlipidemia.
    Kupecz D
    Nurse Pract; 1997 Nov; 22(11):87-8, 90, 93. PubMed ID: 9403876
    [No Abstract]   [Full Text] [Related]  

  • 39. Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No.
    Kendrick M
    BMJ; 2007 May; 334(7601):983. PubMed ID: 17494018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [By JUPITER! Disease mongering!].
    Welin L; Peterson M
    Lakartidningen; 2008 Dec; 105(51-52):3756; discussion 3756-7. PubMed ID: 19278103
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.